Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 9;113(5):1808–1820. doi: 10.1111/cas.15304

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Genomic landscape of circulating tumor DNA (ctDNA) monitoring markers (excluding clonal hematopoiesis (CH)‐related mutations) for 33 estrogen receptor (ER)⁺/human epidermal growth factor receptor 2 (HER2)⁻ metastatic breast cancer patients. (A) Clinicopathological characteristics and mutation matrix of ctDNA alterations. Patients showing no response to cyclin‐dependent kinase (CDK)4/6 inhibitor shown with progressive disease as best clinical response and are grouped to the left. (B) The distribution of alterations according to the respective genes. Percentages calculated using total number of ctDNA alterations detected from 33 patients. CNV, copy number variant; HR, hormone receptor; PR, progesterone receptor; SNV, single nucleotide variant